Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic …
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -183.34 | -713.39 | -251.78 | |
| Graham Fair Price | -31.35 | 4.52 | 6.59 | |
| PEG | 516.38 | 1.39 | 0.23 | |
| Price/Book | 19.06 | -88.20 | -108.97 | |
| Price/Cash Flow | 61.60 | -204.69 | -533.07 | |
| Prices/Earnings | -68.20 | -73.33 | -43.60 | |
| Price/Sales | -28.45 | 39.12 | 54.68 | |
| Price/FCF | 61.60 | -204.69 | -533.07 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 7.68 | 0.87 | 0.80 | |
| Operating Margin | 66.81 | -0.09 | -0.26 | |
| ROA | 52.11 | -0.02 | -0.04 | |
| ROE | 0.62 | 0.30 | -51.88 | |
| ROIC | -0.05 | -0.02 | 61.50 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 1.05 | -99.94 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -1.54 | 0.63 | -59.41 | |
| EPS QOQ | -1.93 | 0.53 | -72.71 | |
| FCF QOQ | -1.13 | -1.09 | 3.26 | |
| Revenue QOQ | -0.41 | 0.12 | -70.01 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 93.45 | 128.21 | 37.20 | |
| Days Sales Outstanding (DSO) | 67.09 | 58.51 | -12.79 | |
| Inventory Turnover | 0.96 | 0.70 | -27.12 | |
| Debt/Capitalization | 1.10 | 1.10 | -0.09 | |
| Quick Ratio | 2.86 | 2.86 | < 0.005 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -1.76 | -1.74 | 1.04 | |
| Cash | 19.42 | 18.80 | -3.20 | |
| Capex | -0.12 | -0.10 | 15.61 | |
| Free Cash Flow | -0.36 | -0.75 | -108.62 | |
| Revenue | 3.50 | 3.92 | 11.95 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad